Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 14-week, randomized, double-blind, placebo-controlled trial of pregabalin twice daily in patients with fibromyalgia

Next Previous
X
Search
Trial Profile

A 14-week, randomized, double-blind, placebo-controlled trial of pregabalin twice daily in patients with fibromyalgia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Acronyms Relief
  • Sponsors Pfizer

    • Most Recent Events

    • 16 Nov 2016 Results post-hoc analysis from pooled data of this and other two studies presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 14 May 2016 Results of a pooled analysis from NCT00645398, NCT00230776, NCT00333866 trials (n=2228) presented at the 35th Annual Scientific Meeting of the American Pain Society
    • 03 May 2014 Results from a pooled analysis presented at the 33rd Annual Scientific Meeting of the American Pain Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top